Abstract

Marine triterpene glycosides are attractive candidates for the development of anticancer agents. Holotoxin A1 is a triterpene glycoside found in the edible sea cucumber, Apostichopus (Stichopus) japonicus. We previously showed that cladoloside C2, the 25(26)-dihydro derivative of holotoxin A1, induced apoptosis in human leukemia cells by activating ceramide synthase 6. Thus, we hypothesized that holotoxin A1, which is structurally similar to cladoloside C2, might induce apoptosis in human leukemia cells through the same molecular mechanism. In this paper, we compared holotoxin A1 and cladoloside C2 for killing potency and mechanism of action. We found that holotoxin A1 induced apoptosis more potently than cladoloside C2. Moreover, holotoxin A1-induced apoptosis in K562 cells by activating caspase-8 and caspase-3, but not by activating caspase-9. During holotoxin A1 induced apoptosis, acid sphingomyelinase (SMase) and neutral SMase were activated in both K562 cells and human primary leukemia cells. Specifically inhibiting acid SMase and neutral SMаse with chemical inhibitors or siRNAs significantly inhibited holotoxin A1–induced apoptosis. These results indicated that holotoxin A1 might induce apoptosis by activating acid SMase and neutral SMase. In conclusion, holotoxin A1 represents a potential anticancer agent for treating leukemia. Moreover, the aglycone structure of marine triterpene glycosides might affect the mechanism involved in inducing apoptosis.

Highlights

  • Acute myeloid leukemia (AML) is a hematologic malignancy characterized by elevated proliferation of myeloid lineage precursors and impaired differentiation of normal hematopoietic progenitor cells [1]

  • We performed the same experiment in other cancer cell lines, and we found that holotoxin A1 induced apoptosis, but the IC50 of holotoxin A1 was different in each cell line (Figure 1C,D)

  • We examined how holotoxin A1 treatment affected the levels of several antiapoptotic proteins, including B-cell lymphoma-2 (Bcl-2), B-cell lymphoma extra-large (Bcl-xL), and myeloid cell leukemia-1 (Mcl-1) and the proapoptotic protein, Bcl-2-associated X protein (Bax)

Read more

Summary

Introduction

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by elevated proliferation of myeloid lineage precursors and impaired differentiation of normal hematopoietic progenitor cells [1]. Despite the various cures available for most leukemias, we remain challenged by cellular resistance to anticancer agents [2]. There is an increasing need for new therapeutic agents to improve the survival rate of patients with leukemia. It was previously reported that ceramide had tumor suppressive properties [3]. Ceramide can be generated by either ceramide synthase or sphingomyelinase (SMase) [4,5].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call